Procedure
Tumors, tumor, death, cardia
TUMOR, RECURRENCE, DISEASE, TUMORS, REGRESSION
Participants were administered three cycles of chemotherapy and PD-1 blockade. For each cycle of treatment, patients were intravenously administered a flat dose of camrelizumab (200 mg) along with a single dose of nab-paclitaxel (260 mg/mIn approximately four to six weeks after the last course of neoadjuvant therapy, a thoracoscopy esophagectomy was performed with cervical esophagogastric anastomosis and total dissection of two-field lymph nodes (LNs). The removal of lymph nodes included recurrent laryngeal nerve nodes, subcarinal nodes, paraesophageal nodes, pulmonary ligament nodes, cardia nodes, left gastric artery nodes, and lesser curvature nodes. Surgical sections were stained with hematoxylin and eosin (H&E), and pathological regression was assessed by two independent pathologists. Complete pathological response (pCR) was defined as the absence of residual invasion disease. Tumors with ≤ 10% residual viable tumor cells were considered as obtaining an MPR.After surgery, follow-up was conducted every 3 months in the first year, every 6 months for the second and third years, and every 12 months thereafter. Overall survival (OS) was defined as the time between the surgery and the end of follow-up or death. Disease-free survival (DFS) was calculated from the surgery date to the end of follow-up or the date of the first recurrence.